Ozempic is making its presence known on menus, and the forecast for dumplings is 100% sunshine.

Patients taking either a GLP-1 or SGLT2 drug had a 74% lower risk of death and an 84% lower risk of a heart attack within an ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

The 13 states where Medicaid covers GLP-1 drugs for obesity are California, Kansas, Minnesota, Wisconsin, Michigan, ...

While Novo currently shares the GLP-1 market with its rival Eli Lilly ... Further, Catalent, operating under the Novo banner, could “charge higher prices, provide worse customer service and ...

A consortium of medical groups are now recommending that most patients who are taking a GLP-1 weight-loss or diabetes drugs continue to take the medications prior to surgery.

The Deep Ellum Foundation is installing new streetlight pole banners on Elm Street ... just came up with something to tempt a whole new customer segment of slimming-down GLP-1 customers nationwide.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

If you're looking for a long-term investment win, these are the ASX shares our Foolish writers say should be on your ticket right now!